VestGen Advisors LLC Makes New $498,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

VestGen Advisors LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 656 shares of the biopharmaceutical company’s stock, valued at approximately $498,000.

A number of other large investors have also added to or reduced their stakes in the company. Smith Group Asset Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $30,417,000. WestEnd Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 43.9% in the third quarter. WestEnd Advisors LLC now owns 27,947 shares of the biopharmaceutical company’s stock valued at $21,194,000 after purchasing an additional 8,528 shares during the last quarter. SYM FINANCIAL Corp grew its stake in Regeneron Pharmaceuticals by 25.1% during the 3rd quarter. SYM FINANCIAL Corp now owns 718 shares of the biopharmaceutical company’s stock valued at $544,000 after purchasing an additional 144 shares in the last quarter. Oakworth Capital Inc. grew its stake in Regeneron Pharmaceuticals by 25.0% during the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 14 shares in the last quarter. Finally, Ashton Thomas Securities LLC increased its holdings in Regeneron Pharmaceuticals by 24.6% during the 3rd quarter. Ashton Thomas Securities LLC now owns 1,706 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 337 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the transaction, the executive vice president owned 12,003 shares in the company, valued at $10,291,252.17. The trade was a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,093 shares of company stock valued at $6,506,845 over the last quarter. Company insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on REGN shares. Piper Sandler increased their target price on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. Leerink Partners lifted their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research note on Monday, August 17th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Tuesday, July 7th. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Finally, Morgan Stanley boosted their target price on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $850.83.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $927.89 on Monday. The firm has a market cap of $95.54 billion, a P/E ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.10. The stock’s 50 day simple moving average is $793.30 and its 200 day simple moving average is $738.05. The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. During the same period in the prior year, the company earned $11.83 earnings per share. The firm’s revenue was up 36.3% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.